The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
Abstract
PURPOSE: The phosphoprotein p53 is involved in transcriptional regulation and is detected in hematologic malignancies. In vitro incubation of acute myelogenous leukemia with OL(1)p53, a 20-mer phosphorothioate oligonucleotide complementary to p53 mRNA, results in leukemic cell death. A phase I dose-escalating trial was conducted to determine the toxicity of OL(1)p53 following systemic administration to patients with hematologic malignancies. PATIENTS AND METHODS: Sixteen patients with either refractory acute myelogenous leukemia (n = 6) or advanced myelodysplastic syndrome (n = 10) participated in the trial. Patients were given OL(1)p53 at doses of 0.05 to 0.25 mg/kg/h for 10 days by continuous intravenous infusion. RESULTS: No specific toxicity was directly related to the administration of OL(1)p53. One patient developed transient nonoliguric renal failure. One patient died of anthracycline-induced cardiac failure. Approximately 36% of the administered dose of OL(1)p53 was recovered intact in the urine. Plasma concentrations and area under the plasma concentration curves were linearly correlated with dose. Leukemic cell growth in vitro was inhibited as compared with pretreatment samples. There were no clinical complete responses. CONCLUSION: A phosphorothioate oligonucleotide, OL(1)p53, can be administered systemically without complications. This type of modified oligonucleotide can be administered without complete degradation, as it was recovered from the urine intact. This oligonucleotide may be useful in combination with currently available chemotherapy agents for the treatment of malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unfortunately, few desired results have been obtained in clinical trials, and no further advancement has been made since 2012.558–560”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [558]
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Molecular themes in oncogenesis
Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,629
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,317
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 620
Wild-type p53 can down-modulate the activity of various promoters.
Ginsberg, D., Mechta‐Grigoriou, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 434
Greiner, T., Moynihan, M., Chan, W., Lytle, D. M., Pedersen, A., Anderson, J., & Weisenburger, D. D. (1996) · Blood · doi:10.1182/blood.v87.10.4302.bloodjournal87104302 · Cited by 285
Self-citationp53 in hematologic malignancies
Imamura, J., Miyoshi, I., & Koeffler, H. (1994) · Blood · doi:10.1182/blood.v84.8.2412.bloodjournal8482412 · Cited by 261
Human p53 gene localized to short arm of chromosome 17
Miller, C. W., Mohandas, T. K., Wolf, D., Prokocimer, M., Rotter, V., & Koeffler, H. P. (1986) · Nature · doi:10.1038/319783a0 · Cited by 215
Prokocimer, M., & Rotter, V. (1994) · Blood · doi:10.1182/blood.v84.8.2391.bloodjournal8482391 · Cited by 185
Bergot, B. J., & Egan, W. (1992) · Journal of Chromatography A · doi:10.1016/0021-9673(92)85456-4 · Cited by 82
Expression of the p53 oncogene in acute myeloblastic leukemia.
Smith, L. J., McCulloch, E. A., & Benchimol, S. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.3.751 · Cited by 52
Bayever, E., Haines, K. M., Iversen, P. L., Ruddon, R. W., Pirruccello, S. J., Mountjoy, C. P., Arneson, M. A., & Smith, L. J. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409059593 · Cited by 48
Self-citationA denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations
Beck, J., Kwitek, A. E., Cogen, P. H., Metzger, A. K., Duyk, G. M., & Sheffield, V. C. (1993) · Human Genetics · doi:10.1007/bf00230217 · Cited by 41
Antisense Oligonucleotide Therapies: Are They the “Magic Bullets”?
Ma, D. D. F., & Doan, T. L. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-2-199401150-00010 · Cited by 24
Pirruccello, S. J., Jackson, J., Lang, M., DeBoer, J. M., Mann, S., Crouse, D. A., Wp, V., Ka, D., & Sharp, J. G. (1992) · Blood · doi:10.1182/blood.v80.4.1026.bloodjournal8041026 · Cited by 9
Self-citationBishop, M. R., Warkentin, P., Jackson, J. D., Bayever, E., Iversen, P. L., Whalen, V. I., Lastovica, J., Haines, K. M., & Kessinger, A. (1994) · PubMed · Cited by 5
Self-citation
Cited by
Sorted by citations
Nucleic-acid therapeutics: basic principles and recent applications
Opalinska, J., & Gewirtz, A. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd837 · Cited by 535
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
Webb, A., Cunningham, D., Cotter, F. E., Clarke, P. A., Stefano, F. D., Ross, P. J., Corbo, M., & Dziewanowska, Z. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11103-x · Cited by 490
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F. I., Stefano, F. D., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Gleave, M. E., & Monia, B. P. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1631 · Cited by 384
Metadata
- Authors
- Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J. O., & Kessinger, A.
- Affiliations
- University of Nebraska Medical Center (US)
- Venue
- Journal of Clinical Oncology
- Published
- 1996-04
- Volume
- 14
- Issue
- 4
- Pages
- 1320-1326
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1821878109
- Cited by
- 136
- References
- 20
- Citations by year
- 2026: 2 · 2023: 2 · 2020: 3 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 1
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Nebraska Medical Center
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- antisense oligonucleotides, phosphorothioate oligonucleotides, p53 mRNA, acute myeloid leukemia, myelodysplastic syndrome, hematologic malignancies, drug toxicity, renal failure, pharmacokinetics, dose escalation
- MeSH terms
- Adult, Aged, Female, Humans, Male, Middle Aged, Molecular Sequence Data, Myelodysplastic Syndromes, Thionucleotides, Leukemia, Myeloid, Acute, Oligonucleotides, Antisense, Treatment Outcome, Oligodeoxyribonucleotides, Antisense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
